MedTrace Logo

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

NCT03392116 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2019-08-20

No results posted yet for this study

Summary

The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects

Conditions

  • Cachexia

Interventions

BIOLOGICAL

NGM120

Subcutaneous Injection

OTHER

Placebo

Subcutaneous Injection

Sponsors & Collaborators

  • NGM Biopharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2019-01-14
Completion
2019-03-11

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03392116 on ClinicalTrials.gov